RMD Financials ResMed

15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Nov 1, 2026, 10:32 UTC Overview →

Growth & profitability

Revenue has grown 12.1% per year over the past 5 years.
Net income has grown faster than revenue (26.3% vs 12.1% per year).
Operating margin has expanded, at 33.4% in the latest year.
Free cash flow has grown 21.1% per year over the past 5 years.

Financial health

The company holds more cash ($1.5B) than total debt ($659M).
Total debt has grown slower than revenue (0.1% vs 12.1% per year).
Total debt is 0.3× EBITDA.

Shareholder returns

Dividends have been paid for 14 consecutive years, consuming 23.0% of earnings and 21.2% of free cash flow.
The dividend has grown 9.1% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2026	$5.7B	$1.5B	61.1%	33.4%	23.1%	17.0%	$1.6B	$659M	$1.5B
2025	$5.1B	$1.4B	59.4%	32.7%	23.5%	17.1%	$1.7B	$668M	$1.2B
2024	$4.7B	$1.0B	56.7%	28.2%	21.0%	14.9%	$1.3B	$707M	$238M
2023	$4.2B	$898M	55.8%	26.8%	21.7%	13.3%	$574M	$1.4B	$228M
2022	$3.6B	$779M	56.6%	28.0%	23.2%	15.3%	$216M	$775M	$274M
2021	$3.2B	$475M	57.5%	28.3%	16.4%	10.0%	$634M	$655M	$295M
2020	$3.0B	$622M	58.1%	27.4%	24.9%	13.6%	$707M	$1.2B	$463M
2019	$2.6B	$405M	57.3%	22.2%	19.5%	9.8%	$390M	$1.3B	$147M
2018	$2.3B	$316M	57.0%	23.2%	15.3%	10.3%	$442M	$281M	$189M
2017	$2.1B	$342M	58.1%	20.6%	17.5%	9.9%	$352M	$1.1B	$822M
2016	—	$352M	—	—	20.8%	10.8%	$489M	$1.2B	$731M
2015	—	$353M	—	—	22.2%	16.2%	—	$301M	$717M
2014	—	$345M	—	—	19.6%	14.6%	—	$301M	$906M
2013	—	$307M	—	—	19.1%	13.9%	$339M	$301M	$876M
2012	—	$255M	—	—	15.9%	11.9%	$336M	$251M	$810M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Sep '26	$1.4B	$418M	61.5%	32.0%	7.0%	5.1%	$374M	$410M	$1.0B
Jun '26	$1.5B	$383M	58.8%	30.7%	5.8%	4.3%	$404M	$659M	$1.5B
Mar '26	$1.4B	$399M	62.2%	34.9%	6.1%	4.5%	$520M	$664M	$1.7B
Dec '25	$1.4B	$393M	61.8%	34.6%	6.2%	4.6%	$311M	$664M	$1.4B
Sep '25	$1.3B	$349M	61.2%	33.4%	5.7%	4.2%	$414M	$669M	$1.4B
Jun '25	$1.3B	$380M	60.8%	33.7%	6.4%	4.6%	$508M	$668M	$1.2B
Mar '25	$1.3B	$365M	59.3%	33.0%	6.6%	4.8%	$558M	$673M	$933M
Dec '24	$1.3B	$345M	58.6%	32.5%	6.6%	4.8%	$288M	$673M	$522M
Sep '24	$1.2B	$311M	58.6%	31.6%	6.0%	4.3%	$308M	$677M	$426M
Jun '24	$1.2B	$292M	58.5%	31.2%	6.0%	4.3%	$415M	$707M	$238M
Mar '24	$1.2B	$300M	57.9%	31.3%	6.5%	4.4%	$381M	$1.0B	$238M
Dec '23	$1.2B	$209M	55.6%	23.7%	4.7%	3.0%	$249M	$1.2B	$210M
Sep '23	$1.1B	$219M	54.4%	26.2%	5.2%	3.3%	$256M	$1.4B	$209M
Jun '23	$1.1B	$230M	55.0%	24.5%	5.6%	3.4%	$203M	$1.4B	$228M
Mar '23	$1.1B	$233M	55.3%	26.9%	5.9%	3.5%	$254M	$1.6B	$228M
Dec '22	$1.0B	$225M	56.1%	27.1%	6.0%	3.4%	$101M	$1.8B	$253M
Sep '22	$950M	$210M	56.9%	29.0%	6.1%	4.1%	$16M	$795M	$207M
Jun '22	$915M	$195M	57.1%	27.9%	5.8%	3.8%	$51M	$775M	$274M
Mar '22	$865M	$179M	56.8%	27.1%	5.5%	3.6%	$69M	$681M	$202M
Dec '21	$895M	$202M	56.4%	27.8%	6.4%	4.3%	$189M	$680M	$194M

Valuation over time

How the market has priced RMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 39.5× (Mar '23) to 21.5× (Nov '26).
The price-to-sales ratio has fallen from 8.6× (Mar '23) to 5.8× (Nov '26).
The dividend yield has risen from 0.8% (Mar '23) to 1.1% (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is RMD growing its revenue and profit?

Over the past 5 years, ResMed's revenue has grown 12.1% per year, and net income grown 26.3% per year. These are computed facts, not advice.

How much debt does RMD have?

As of FY2026, ResMed reported $659M of total debt against $1.5B of cash.

What is RMD's profit margin?

In FY2026, gross margin was 61.1%, operating margin 33.4%, and net margin 26.9%.

What is RMD's P/E ratio?

ResMed's P/E (TTM) is 20.56 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the RMD stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 21.5× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.